| Autor: |
Maliga Z; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Kim DY; Harvard-MIT Health Sciences and Technology Program, Harvard Medical School, Boston, Massachusetts, USA., Bui AN; Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA., Lin JR; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Dewan AK; Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Jadeja S; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Murphy GF; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Nirmal AJ; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Lian CG; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Sorger PK; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., LeBoeuf NR; Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: nleboeuf@partners.org. |
